Everolimus plus exemestane as first-line therapy in HR(+), HER2 (-) advanced breast cancer in BOLERO-2.

Authors : Beck JT, Hortobagyi GN, Campone M, Lebrun F, Deleu I, Rugo HS, Pistilli B, Masuda N, Hart L, Melichar B, Dakhil S, Geberth M, Nunzi M, Heng DY, Brechenmacher T, El-Hashimy M, Douma S, Ringeisen F, Piccart-Gebhart M
Year : 2014
Journal : Breast Cancer Res. Treat.
Volume : 143(3)
Pages : 459-67